Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer ...

IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 ...

The FDA approved the PD-1 inhibitor penpulimab, with two indications, for treating non-keratinizing nasopharyngeal carcinoma ...

IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 immune checkpoint blockade, enhancing immunogenic cell death and T cell ...

The FDA has approved Akeso’s penpulimab-kcqx, a PD-1 monoclonal antibody, for two indications treating nasopharyngeal carcinoma (NPC). The drug is now indicated in combination with chemotherapy as a ...

1c). This result further emphasizes the efficacy of treatment with monoclonal antibody against CD40 and confirms the data obtained in the DBA/1–TcR-β transgenic mice. Figure 5: Treatment with ...